Compare · AZYO vs HUM
AZYO vs HUM
Side-by-side comparison of Aziyo Biologics Inc. (AZYO) and Humana Inc. (HUM): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both AZYO and HUM operate in Medical Specialities (Health Care), so they compete in similar markets.
- HUM is the larger of the two at $43.76B, about 535.2x AZYO ($81.8M).
- HUM has hit the wire 5 times in the past 4 weeks while AZYO has been quiet.
- HUM has more recent analyst coverage (25 ratings vs 1 for AZYO).
- Company
- Aziyo Biologics Inc.
- Humana Inc.
- Price
- $1.49+2.05%
- $364.43+0.36%
- Market cap
- $81.8M
- $43.76B
- 1M return
- -
- +32.89%
- 1Y return
- -
- +57.14%
- Industry
- Medical Specialities
- Medical Specialities
- Exchange
- NASDAQ
- NYSE
- IPO
- 2020
- News (4w)
- 0
- 5
- Recent ratings
- 1
- 25
Aziyo Biologics Inc.
Aziyo Biologics, Inc., a regenerative medicine company, focuses on the development of regenerative medical products to address the implantable electronic device/cardiovascular, orthopedic/spinal repair, and soft tissue reconstruction markets. It offers CanGaroo that combines the envelope with antibiotics and is designed to reduce the risk of infection following surgical implantation of an electronic device; and cardiovascular products, such as ProxiCor for use as an intracardiac patch or pledget for tissue repairs; Tyke for use in neonates and infants to repair pericardial structures; and VasCure, a patch material to repair or reconstruct the peripheral vasculature, including the carotid, renal, iliac, femoral, and tibial blood vessels for cardiovascular, vascular, and general surgeons. The company also provides FiberCel, ViBone, and OsterGro V that are designed to protect and preserve native bone cells; and SimpliDerm, a pre-hydrated HADM designed to repair or replacement of damaged or inadequate integumental tissues. In addition, it offers contract manufacturing services for various products to corporate customers. The company sells its products to hospitals and other healthcare facilities through its direct sales force, commercial partners, and independent sales agents. Aziyo Biologics, Inc. was incorporated in 2015 and is headquartered in Silver Spring, Maryland.
Humana Inc.
Humana Inc., together with its subsidiaries, operates as a health and well-being company in the United States. It operates through Retail, Group and Specialty, and Healthcare Services segments. The company offers medical and supplemental benefit plans to individuals. It also has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits. In addition, the company provides commercial fully-insured medical and specialty health insurance benefits comprising dental, vision, and other supplemental health benefits; and administrative services only products to individuals and employer groups, as well as military services, such as TRICARE T2017 East Region contract. Further, it offers pharmacy solutions, provider services, predictive modeling and informatics services, and clinical care services, such as home health and other services to its health plan members, as well as to third parties. As of December 31, 2020, the company had approximately 17 million members in medical benefit plans, as well as approximately 5 million members in specialty products. Humana Inc. was incorporated in 1964 and is headquartered in Louisville, Kentucky.
Latest AZYO
- SEC Form SC 13G filed by Aziyo Biologics Inc.
- SEC Form 424B3 filed by Aziyo Biologics Inc.
- SEC Form SC 13G/A filed by Aziyo Biologics Inc. (Amendment)
- SEC Form 4 filed by Mills C Randal
- SEC Form 4 filed by Ferguson Matthew
- SEC Form 4 filed by Williams Michelle Leroux
- Aziyo Biologics Inc. filed SEC Form 8-K: Leadership Update, Other Events, Financial Statements and Exhibits
- SEC Form S-8 filed by Aziyo Biologics Inc.
- Aziyo Biologics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits
- Aziyo Biologics Inc. filed SEC Form 8-K: Other Events
Latest HUM
- Humana Announces Agreement to Divest Minority Interest in Gentiva
- Humana Inc. filed SEC Form 8-K: Regulation FD Disclosure
- Humana completes $83 million Florida infrastructure investment to deepen coordinated patient care approach
- Humana upgraded by Deutsche Bank with a new price target
- Humana Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Financial Statements and Exhibits
- Humana, CenterWell and USAA Unite with VFW for National Day of Service Supporting Veterans Experiencing Homelessness
- Humana Invests More Than $1 Million to Advance Health Outcomes Across Louisiana
- Chief Financial Officer Mellet Celeste gave a grant of 15,387 units of Humana Common, decreasing direct ownership by 28% to 39,637 units (SEC Form 4)
- Chief Information Officer Mehta Japan was granted 9,448 units of Humana Common, increasing direct ownership by 122% to 17,176 units (SEC Form 4)
- President, Enterprise Growth Dintenfass David was granted 11,273 units of Humana Common, increasing direct ownership by 80% to 25,407 units (SEC Form 4)